Description
The FDA accepts Nicox’s NDA for an investigational glaucoma drop; Bausch + Lomb provides updates on two key investigational therapies for dry eye and ocular surface pain; and Ocugen doses the first patient in a global phase 3 trial of an investigational gene therapy for geographic atrophy (GA).
Learn more about your ad choices. Visit megaphone.fm/adchoices
/https%3A%2F%2Fmegaphone.imgix.net%2Fpodcasts%2F76175cb8-6a11-11ef-a54a-87470a073a58%2Fimage%2Fa6563563ccdf4f408d6aad7c3182e268.jpg%3Fixlib%3Drails-4.3.1%26max-w%3D3000%26max-h%3D3000%26fit%3Dcrop%26auto%3Dformat%2Ccompress)
/https%3A%2F%2Fmegaphone.imgix.net%2Fpodcasts%2F76175cb8-6a11-11ef-a54a-87470a073a58%2Fimage%2Fa6563563ccdf4f408d6aad7c3182e268.jpg%3Fixlib%3Drails-4.3.1%26max-w%3D3000%26max-h%3D3000%26fit%3Dcrop%26auto%3Dformat%2Ccompress)